The invention relates to a home monitoring device deployed at the patient’s residence, a system with multiple supposed drawbacks.
RetinalGeniX Technologies has received a patent for its patient home monitoring and integrated physician alert system for ocular anatomy.
Designed to send an alert to a physician located remotely, the invention pertains to a home monitoring device installed at the patient’s residence.
The physician can then conduct a preliminary evaluation from a distance to determine if an in-person medical diagnosis is necessary.
In conjunction with RetinalGeniX’s DNA/GPS technology, the new patented system is expected to assist in the early diagnosis of systemic diseases by deploying high-resolution remote retinal imaging and real-time monitoring from the home.
RELATED: Siemens Healthineers Launches Atellica CI Analyzer Compact Testing System
According to the company, the existing eye care model, where patients need to schedule in-person visits with eye specialists, has multiple drawbacks.
The company also stated that over 500 million people globally experience severe eye conditions but a sufficient number of ophthalmologists and optometrists are not available in the US and worldwide for screening, examining, diagnosing and treating these diabetic patients.
RetinalGeniX believes that it is crucial to establish a remote health monitoring system, which would empower patients to oversee their well-being from a distance, eliminating the need for frequent in-person office visits for screenings or non-diagnostic evaluations.
This ensures that patients can conveniently manage their health from the comfort of their own homes, free from any inconvenience.
RetinalGeniX CEO Jerry Katzman said: “The current diagnostic process is neither timely nor cost-effective if a patient cannot physically visit the emergency room, doctor’s office or laboratory.
“RetinalGeniX is leading the charge in embracing this paradigm shift and we fully expect the imminent emergence of pharmaco-genetic mapping enhanced home diagnostics.”
